Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Filer	Shares	Latest Filing Date	Previously owned	Change	Share-Type	Market Value
Ra Capital Management, L.P.	13.15M	2023-08-14	13.15M	0	Shares	36.82M
Bml Capital Management, Llc	1.58M	2023-07-24	1.66M	-75K	Shares	4.43M
Atom Investors Lp	78.89K	2023-08-14	78.89K	0	Shares	220.88K
Amalgamated Financial Corp.	1.04K	2022-05-16	0	1.04K	Shares	9K

NASDAQ:ELYM

Eliem Therapeutics, Inc.

Last Close

8.39

03/05 20:00

Market Cap

79.27M

Beta: -

Volume Today

1.47M

Avg: 17.85K

PE Ratio

−1.98

PFCF: −2.60

Institutional trades

Institutional Ownership

Current holdings institutionals